Skip to content

A Prospective Cohort Study of Compound Nanxing Zhitong Ointment

A Prospective Cohort Study of Compound Nanxing Zhitong Ointment in the Treatment of Chronic Musculoskeletal Pain

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05201365
Enrollment
3000
Registered
2022-01-21
Start date
2022-01-31
Completion date
2024-01-31
Last updated
2022-01-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Musculoskeletal Pain

Brief summary

The purpose of this study is to evaluate the safety and the efficacy of compound Nanxing pain relief cream in the treatment of chronic pain in the musculoskeletal system

Detailed description

Chronic pain, especially in the musculoskeletal system, is prevalent worldwide. Many studies show the burdens they impose: pain, disability, reduced quality of life (QoL), marked impairment of participation in work and social activities, and heavy financial costs.The purpose of this study is to evaluate the safety and the efficacy of compound Nanxing pain relief cream in the treatment of chronic pain in the musculoskeletal system. To provide a safe and effective treatment of Chronic Musculoskeletal Pain.

Interventions

None listed

Sponsors

Jiangsu Kanion Pharmaceutical Co., Ltd
Lead SponsorINDUSTRY

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* Attendance at orthopedic, rheumatology and pain clinics for.

Exclusion criteria

* Indication for surgery.

Design outcomes

Primary

MeasureTime frameDescription
Change in Overall Pain Assessment Scale score at week 12 overall Pain Assessment Scale score at week 12.Change from Baseline GPS at week 12.Evaluation using Global pain scale, GPS。The change of pain assessment scale score from the beginning period of the treatment to the end indicates the effectiveness of the treatment. The GPS is based on patients' subjective and objective perceptions, and is used to measure patients' overall perceptions of pain. The scores were distributed from 0 to 10, with 0 representing no pain at all and 10 representing the most painful, and the scores were summarized and tallied. Higher scores indicate more severe pain effects.

Secondary

MeasureTime frameDescription
Quality of Life Short Form12,SF-12Total scores at baseline, week 2, week 4, week 8, and week 12 were evaluated in both groups.SF-12 The raw scores of the 7 dimensions were calculated separately. The scores ranged from 0 to 100, with 0 being the worst and 100 being the best.
Pain resolution timeVAS is assessed within 1 hour ahead of the treatment and within 1 hour after the treatment. The change of the score indicate the treatment efficacy.Visual analog scale(VAS) is used to test the painful degree. The time taken for a pain VAS score of ≤2 to be maintained for 24 hours or more.
Number of pain-free days per monthRecords are taken every day by the end of the day. Records are assessed at the end of 12 weeks of treatment.Record the number of days per month that the patient is pain-free in the affected area.
Chinese medicine evidence scoreThe TCM evidence score was assessed within 1 hour after treatment. Changes in TCM evidence scores compared to baseline at week 12.The scale is divided into 2 main aspects, primary and secondary conditions. There are 2 entries for the primary condition. The secondary condition has 8 entries. The entries are scored as 0, 2, 4, and 6 depending on the severity of the symptoms. The total score is 36. The higher the score, the more severe the symptoms.
Safety evaluationAfter 12 weeks of treatment, evaluate adverse reactions and make a record.Safety rating includes 4 levels.Level 1 means Safe, without any adverse reactions.Level 2 means Safer, if there is an adverse reaction, you can continue treatment without any treatment .Level 3 means Have safety problems, have moderate adverse reactions, and continue treatment after treatment. Level 4 means Suspension test due to adverse reactions. Incidence of adverse events andadverse drug reactions.

Contacts

Primary Contactchen weiheng, M.D.
drchenweiheng@163.com13511013261
Backup Contactkang pengdr, M.D.
kangpd@163.com18980601953

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026